DSM Biomedical
To meet the upcoming needs of the medical and biotech industries, DSM Biomedical builds on the expertise and strengths of DSM in polymers, coating technology, materials science and life sciences. DSM’s current biomedical portfolio includes ComfortCoat™ hydrophilic and antimicrobial coating technology for catheters, guidewires and stent delivery systems and Dyneema Purity®, a high performance polyethylene fiber technology, which has been developed specifically for use in medical applications, such as orthopedic implants. Recently the company acquired PTG, a market leader in the field of biomedical polymers Furthermore, a research and development program specifically aimed at extending DSM’s material portfolio for the orthopedic industry has been started. DSM Biomedical is also focusing on developing materials and systems around implantable devices for the musculoskeletal and vascular systems and drug delivery devices in musculoskeletal, vascular and ophthalmic application areas. For more information, visit www.dsmbiomedical.com.
DSM - Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 24,500 employees deliver annual net sales of around €10 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.
Forward-looking statements
This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
DSM BiomedicalPostal address:
P.O. Box 18
6160 MD Geleen
The Netherlands
Visiting address:
Koestraat 1
6167 RA Geleen
Netherlands
16 Sep 2008
DSM Biomedical obtains ISO certification
DSM Biomedical has obtained ISO 13485 certification in recognition of its quality management systems for its medical coating activities. This ISO certification broadens DSM’s access as a qualified supplier in the medical market. ISO certifications for DSM PTG and Dyneema Purity® were already in place.
30 Jun 2008
DSM Biomedical receives funding from public-private partnership in biomedical materials
Today DSM Biomedical announced that it will receive funding from the Biomedical Materials Program (BMM), a Dutch public-private partnership in biomedical materials. In total BMM allocated over 50 million Euros to seven R&D projects, four of which were initiated by DSM Biomedical. The funding will help DSM Biomedical to expand its R&D portfolio and accelerate the development time of new biomedical materials, thus contributing to the realization of DSM’s ambition to become a leading player in the biomedical market.
29 Feb 2008
DSM expands biomedical portfolio
DSM Biomedical today announced the start of a development program of polyester based Thermoplastic Elastomers (TPE) for use in medical devices. In the coming years DSM Biomedical will work together with medical device companies to develop tailored TPE material grades. These grades will be specifically aimed at making orthopedic devices perform better or, alternatively, at enabling the development of novel products and therapies.
31 Oct 2007
DSM Biomedical Chairs Session on Antimicrobial Surfaces at BioInterface 2007
SAN MATEO, Calif. – Oct. 31, 2007 – At the BioInterface 2007 Workshop and Symposium, Aylvin Dias, Ph.D, R&D program manager for DSM Biomedical, will chair a double session on antimicrobial surfaces with emphasis on biofilms, biofouling and biocidal approaches. This session will be attended by a number of industrial and academic opinion leaders to discuss the latest developments on and challenges to medical device associated infections. During the session, Dr. Dias will introduce ComfortCoat™, DSM’s new coating that addresses catheter associated urinary tract infections (CAUTI).
14 Sep 2007
DSM starts initiative to extend its material portfolio for the orthopedic industry
DSM today announced the start of an initiative to enter the market of ultra high molecular weight polyethylene (UHMWPE) for use in Total Joint Arthroplasty and other medical devices. In the upcoming years DSM Biomedical will make significant investments in a research and development program focused on UHMWPE-grades with optimized material properties, specifically aimed at currently unmet clinical needs in this orthopedic segment. This strategic material development links on to DSM’s activities in the Emerging Business Area of Biomedical Materials, which is an important element of DSM’s strategy Vision 2010 – Building on Strengths.